# Winners take it all: turning cell competition into a therapeutic ally

**Authors:** Tereza Fantová, Maxima Warmuzová, Sandra Charvátová, Kateřina Stošková, Tomáš Jelínek, Michal Šimíček, Roman Hájek, Juli R. Bagó

PMC · DOI: 10.1186/s12964-025-02611-3 · 2026-01-07

## TL;DR

Cell competition, where healthy cells eliminate unhealthy ones, could lead to new treatments for diseases like cancer.

## Contribution

The paper categorizes therapeutic opportunities based on the physiological settings of cell competition.

## Key findings

- Cell competition acts as a natural quality control mechanism eliminating unfit or malignant cells.
- Cancer cells can exploit cell competition to promote tumor growth.
- Understanding context-dependent mechanisms opens new therapeutic possibilities.

## Abstract

Recent discoveries in the field of cell competition have brought this phenomenon into the spotlight due to its potential to inspire novel therapeutic approaches for previously incurable diseases.

Cell competition, a process observed across multicellular organisms, acts as a natural quality control mechanism in which unfit, abnormal, or malignant cells are actively eliminated by neighboring, healthy-fit cells. However, the mechanisms and outcomes of cell competition are highly context-dependent, influenced by the environment, developmental stage, and specific tissue involved. Emerging research also highlights a darker aspect where cancer cells can hijack cell competition to their advantage, promoting tumor growth and progression. A deeper understanding of cell competition opens up a wide range of therapeutic possibilities for diseases that currently lack effective treatments. Given its specificity and context-dependence, we categorize these therapeutic opportunities based on the physiological settings in which cell competition occurs.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, VIM (vimentin) [NCBI Gene 7431], FLNC (filamin C) [NCBI Gene 2318] {aka ABP-280, ABP280A, ABPA, ABPL, ARVC15, CMD1PP}, MSN (moesin) [NCBI Gene 4478] {aka HEL70, IMD50}, Myc (Myc proto-oncogene, bHLH transcription factor) [NCBI Gene 17869] {aka Myc2, Niard, Nird, bHLHe39}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, DSPP (dentin sialophosphoprotein) [NCBI Gene 1834] {aka DFNA39, DGI1, DMP3, DPP, DSP}, Bcl2l1 (BCL2-like 1) [NCBI Gene 12048] {aka Bcl(X)L, Bcl-XL, Bcl2l, BclX, bcl-x, bcl2-L-1}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, Dnmt3a (DNA methyltransferase 3A) [NCBI Gene 13435] {aka MmuIIIA}, PLEC (plectin) [NCBI Gene 5339] {aka EBS1, EBS5A, EBS5B, EBS5C, EBS5D, EBSMD}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, FLNA (filamin A) [NCBI Gene 2316] {aka ABP-280, ABPX, CSBS, CVD1, FGS2, FLN}, Yap1 (yes-associated protein 1) [NCBI Gene 22601] {aka Yap, Yap65, Yki, Yorkie}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Vim (vimentin) [NCBI Gene 22352], MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Notum (notum palmitoleoyl-protein carboxylesterase) [NCBI Gene 77583] {aka 5730593N15Rik}, MYCL (MYCL proto-oncogene, bHLH transcription factor) [NCBI Gene 4610] {aka L-Myc, LMYC, MYCL1, bHLHe38}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, RIPK3 (receptor interacting serine/threonine kinase 3) [NCBI Gene 11035] {aka RIP3}, bsk (basket) [NCBI Gene 44801] {aka Basket, CG5680, D-JNK, D-junk, DBSK/JNK, DJNK}, RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737] {aka AIEFL, IMD57, RIP, RIP-1, RIP1}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, RpS17 (Ribosomal protein S17) [NCBI Gene 39088] {aka BcDNA:RE44119, CG3922, D9, Dmel\CG3922, M, M(3)67}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, Bax (BCL2-associated X protein) [NCBI Gene 12028], LILRB3 (leukocyte immunoglobulin like receptor B3) [NCBI Gene 11025] {aka CD85A, HL9, ILT-5, ILT5, LIR-3, LIR3}, Col17a1 (collagen, type XVII, alpha 1) [NCBI Gene 12821] {aka BP180, Bpag, Bpag2}, PTK6 (protein tyrosine kinase 6) [NCBI Gene 5753] {aka BRK}, Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) [NCBI Gene 20525] {aka GT1, Glut-1, Glut1, M100200, Rgsc200}, GRK1 (G protein-coupled receptor kinase 1) [NCBI Gene 6011] {aka GPRK1, RHOK, RK}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, S1pr1 (sphingosine-1-phosphate receptor 1) [NCBI Gene 13609] {aka Edg1, Lpb1, S1p, S1p1}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, Ifna (interferon alpha complex region) [NCBI Gene 111654] {aka Ifa, Ifa8}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, TSPAN31 (tetraspanin 31) [NCBI Gene 6302] {aka SAS}, RHO (rhodopsin) [NCBI Gene 6010] {aka CSNBAD1, OPN2, RP4}, Tnfrsf1b (tumor necrosis factor receptor superfamily, member 1b) [NCBI Gene 21938] {aka CD120b, TNF-R-II, TNF-R2, TNF-R75, TNF-alphaR2, TNFBR}
- **Diseases:** UPCs (MESH:D014555), tumorigenesis (MESH:D063646), WT (MESH:D002292), hypertrophy (MESH:D006984), colorectal cancer (MESH:D015179), decline in motor function (MESH:D003291), cardiovascular diseases (MESH:D002318), skin fragility (MESH:C536183), AD (MESH:D000544), epidermal injury (MESH:D004814), liver metastasis (MESH:D009362), hematologic malignancies (MESH:D019337), atrophy (MESH:D001284), genetic abnormalities (MESH:D030342), age-related diseases (MESH:D010024), EDAC (MESH:D009369), EPLIN (MESH:D009375), leukemia (MESH:D007938), neurodegeneration (MESH:D019636), skin thinning (MESH:D013851), locomotor impairments (MESH:D001523), Adenomatous polyposis coli (MESH:D011125), hyperplasia (MESH:D006965), musculoskeletal disorders (MESH:D009140), teratoma (MESH:D013724)
- **Chemicals:** Y27632 (MESH:C108830), R-PFI-2 (MESH:C000592938), BH3 (MESH:C006008), CAR-T (-), metformin (MESH:D008687), apocynin (MESH:C056165), Sphingosine-1-phosphate (MESH:C060506), glucose (MESH:D005947), lithium chloride (MESH:D018021)
- **Species:** Diptera (flies, order) [taxon 7147], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Drosophila melanogaster (fruit fly, species) [taxon 7227]
- **Cell lines:** CAR-T — Mus musculus (Mouse), Transformed cell line (CVCL_WN86), MDCK — Canis lupus familiaris (Dog), Spontaneously immortalized cell line (CVCL_0422)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12870730/full.md

---
Source: https://tomesphere.com/paper/PMC12870730